Phase II open-label study of sunitinib malate (SU011248) in adult patients with metastatic and/or surgically unresectable soft tissue sarcoma.

Trial Profile

Phase II open-label study of sunitinib malate (SU011248) in adult patients with metastatic and/or surgically unresectable soft tissue sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2012

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Leiomyosarcoma; Liposarcoma; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top